

# TENECTEPLASE

SYNONYMS	TNK
BRAND NAME	METALYSE
DRUG CLASS	Thrombolytic
AVAILABILITY	Vial contains 40 mg (8000 units) or 50 mg (10 000 units) of tenecteplase. Also contains L-arginine, phosphoric acid and polysorbate-20. Prefilled diluent syringes contain 8 mL and 10 mL of water for injections respectively. <sup>1</sup>
WARNING	<div style="border: 2px solid red; padding: 5px;"><p>Use only where staff are trained in advanced life support and where there is access to resuscitation equipment including a defibrillator.<sup>1,2</sup></p><p>The dosing information on the syringe is not suitable for all patients.<sup>2,3</sup> Check your local guidelines.</p></div>
pH	No information
PREPARATION	<p>Remove the cap from the prefilled syringe and screw onto the vial adaptor. Push the spike of the vial adaptor into the vial and slowly inject the diluent. Swirl gently to dissolve.<sup>1</sup> <b>Do not shake.</b></p> <p>The concentration is 5 mg/mL (1000 units/mL). The solution is clear and colourless to pale yellow.<sup>1</sup></p>
STABILITY	<p>Vial: store below 30 °C. Protect from light.<sup>1</sup></p> <p>Reconstituted solution: stable for 8 hours at 30 °C or for 24 hours at 2 to 8 °C.<sup>1</sup></p>
ADMINISTRATION	
<b>IM injection</b>	Not recommended <sup>1</sup>
<b>SUBCUT injection</b>	Not recommended <sup>1</sup>
<b>IV injection</b>	<p>For patients with a STEMI, inject over 10 seconds.<sup>1</sup> Flush the line with sodium chloride 0.9% before and after injection to avoid precipitation in the line.<sup>1</sup></p> <p>When used for thrombolysis in acute ischaemic stroke only, may be injected over 5 seconds.<sup>3</sup> Check your local guidelines.</p>
<b>IV infusion</b>	Not recommended <sup>1</sup>
COMPATIBILITY	
<b>Fluids</b>	Sodium chloride 0.9% <sup>1</sup>
<b>Y-site</b>	Not recommended <sup>1</sup>
INCOMPATIBILITY	
<b>Fluids</b>	Glucose solutions <sup>1</sup>
<b>Drugs</b>	No information
SPECIAL NOTES	<p>Monitor for signs of bleeding especially at vascular puncture and access sites.<sup>1</sup></p> <p>Anaphylactic reactions have been reported.<sup>1</sup></p> <p>Do not use in patients with known hypersensitivity to gentamicin, as very small amounts may be present due to the manufacturing process of tenecteplase.<sup>1</sup></p> <p>Tenecteplase units are not comparable to units used for other thrombolytic drugs.<sup>1</sup></p>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 17/09/2020.
2. Acute coronary syndromes [March 2018]. In: eTG complete [internet]. Melbourne: Therapeutic Guidelines Limited; August 2020.
3. Australian Clinical Guidelines for Stroke Management: acute medical and surgical management. Melbourne: Stroke Foundation; 2019. Available from [www.informme.org.au](http://www.informme.org.au). Accessed 16/09/2020.